BR112012022688A2 - proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão - Google Patents
proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusãoInfo
- Publication number
- BR112012022688A2 BR112012022688A2 BR112012022688A BR112012022688A BR112012022688A2 BR 112012022688 A2 BR112012022688 A2 BR 112012022688A2 BR 112012022688 A BR112012022688 A BR 112012022688A BR 112012022688 A BR112012022688 A BR 112012022688A BR 112012022688 A2 BR112012022688 A2 BR 112012022688A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- vaccine
- polynucleotide
- disease
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão a presente invenção diz respeito ao campo de composições e vacinas imunogênicas contra neisseria, sua fabricação, e ao uso de tais composições na medicina. as proteínas fhbp quimérica (proteína de ligação do fator h), e composições que compreendem as ditas proteínas, são descritas para superar o problema de resposta imune à fhbp, que é específica para cepa meningocócia, a partir das quais a fhbp foi derivada.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31255010P | 2010-03-10 | 2010-03-10 | |
US31257410P | 2010-03-10 | 2010-03-10 | |
US31258210P | 2010-03-10 | 2010-03-10 | |
US31279210P | 2010-03-11 | 2010-03-11 | |
US31279910P | 2010-03-11 | 2010-03-11 | |
US31280410P | 2010-03-11 | 2010-03-11 | |
PCT/EP2011/053630 WO2011110634A1 (en) | 2010-03-10 | 2011-03-10 | Vaccine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012022688A2 true BR112012022688A2 (pt) | 2018-05-22 |
Family
ID=43983531
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022676A BR112012022676A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit |
BR112012022669A BR112012022669A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
BR112012022688A BR112012022688A2 (pt) | 2010-03-10 | 2011-03-10 | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022676A BR112012022676A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit |
BR112012022669A BR112012022669A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
Country Status (7)
Country | Link |
---|---|
US (4) | US20130004530A1 (pt) |
EP (3) | EP2544713A1 (pt) |
JP (4) | JP2013521326A (pt) |
CN (3) | CN103002910A (pt) |
BR (3) | BR112012022676A2 (pt) |
CA (3) | CA2792683A1 (pt) |
WO (3) | WO2011110634A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2373236C (en) | 1999-05-19 | 2014-08-26 | Chiron S.P.A. | Combination neisserial compositions |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
ES2532946T3 (es) | 2008-02-21 | 2015-04-06 | Novartis Ag | Polipéptidos PUfH meningocócicos |
CN104548082A (zh) | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
CN103002910A (zh) * | 2010-03-10 | 2013-03-27 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物 |
WO2012025873A2 (en) | 2010-08-23 | 2012-03-01 | Wyeth Llc | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
US10598666B2 (en) | 2012-03-08 | 2020-03-24 | Glaxosmithkline Biologicals Sa | In vitro potency assay for protein-based meningococcal vaccines |
SG10201602558UA (en) | 2012-03-09 | 2016-05-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
CA2876138C (en) * | 2012-06-14 | 2023-09-19 | Novartis Ag | Vaccines for serogroup x meningococcus |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN104248755A (zh) * | 2013-10-30 | 2014-12-31 | 普莱柯生物工程股份有限公司 | 一种副猪嗜血杆菌病疫苗组合物及其制备方法和应用 |
RS61246B1 (sr) | 2014-02-28 | 2021-01-29 | Glaxosmithkline Biologicals Sa | Modifikovani meningokokni fhbp polipeptidi |
CA2954745A1 (en) | 2014-07-17 | 2016-01-21 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
BE1022878B1 (fr) * | 2014-07-17 | 2016-09-30 | Glaxosmithkline Biologicals Sa | Vaccins anti-meningococciques |
BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
EP3298031B1 (en) * | 2015-05-18 | 2020-10-21 | BiOMVis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
CA3035320A1 (en) * | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
BR102020013216A2 (pt) * | 2020-06-26 | 2022-03-08 | Instituto Butantan | Processo de obtenção de vesículas apresentadoras de antígenos (vaa) que possibilita o acoplamento de um ou mais antígenos |
JP2024507828A (ja) * | 2021-02-19 | 2024-02-21 | サノフィ パスツール インコーポレイテッド | B群髄膜炎菌組換えワクチン |
CN113896799B (zh) * | 2021-09-10 | 2023-07-21 | 江苏南农高科技股份有限公司 | 一种融合蛋白、融合蛋白疫苗及其制备方法、应用 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
DE3071552D1 (en) | 1979-09-21 | 1986-05-22 | Hitachi Ltd | Semiconductor switch |
US4271147A (en) | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
JP3237842B2 (ja) | 1988-12-16 | 2001-12-10 | オランダ国 | ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン |
DE69133276T2 (de) | 1990-07-16 | 2003-11-27 | Univ North Carolina | Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis |
CA2087958C (en) | 1990-08-23 | 2007-05-15 | P. Frederick Sparling | Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis |
US5912336A (en) | 1990-08-23 | 1999-06-15 | University Of North Carolina At Chapel Hill | Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5371186A (en) | 1991-02-11 | 1994-12-06 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
US5652211A (en) | 1991-02-11 | 1997-07-29 | Biosynth S.R.L. | Peptides for neutralizing the toxicity of Lipid A |
US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
FR2682041B1 (fr) | 1991-10-03 | 1994-01-14 | Pasteur Merieux Serums Vaccins | Vaccin contre les infections a neisseria meningitidis. |
JPH07503982A (ja) | 1992-01-13 | 1995-04-27 | アクゾ ノーベル ナムローゼ フェンノートシャップ | エンジニアリングプラスチックを伴うゴムの架橋 |
ATE245446T1 (de) | 1992-02-11 | 2003-08-15 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
HU219808B (hu) | 1992-06-25 | 2001-08-28 | Smithkline Beecham Biologicals S.A. | Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására |
GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
WO1994026304A1 (en) | 1993-05-18 | 1994-11-24 | Ohio State Research Foundation | Otitis media vaccine |
US6361779B1 (en) | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
DE69434839T2 (de) | 1993-11-08 | 2007-10-25 | Sanofi Pasteur Ltd., Toronto | Transferrin-rezeptor-gene von haemophilus |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
JPH11507214A (ja) | 1995-06-07 | 1999-06-29 | バイオケム ヴァシーンズ インク. | Hsp70ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6440701B1 (en) | 1996-03-08 | 2002-08-27 | Aventis Pasteur Limited | Transferrin receptor genes of Moraxella |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
EP0912608B1 (en) | 1996-05-01 | 2006-04-19 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
FR2751000B1 (fr) | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
EP1770164B1 (en) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
ATE380867T1 (de) | 1997-06-03 | 2007-12-15 | Sanofi Pasteur Ltd | Lactoferrinrezeptorgen von moraxella |
KR100619350B1 (ko) | 1997-07-21 | 2006-09-05 | 박스터 헬쓰케어 에스.에이. | 변형 면역성 뉴멀리신 백신조성물 |
CA2301332A1 (en) | 1997-08-15 | 1999-02-25 | University Of Utrecht | Neisseria lactoferrin binding protein |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
CN1200731C (zh) | 1998-04-07 | 2005-05-11 | 免疫医疗公司 | 用作疫苗的肺炎球菌胆碱结合蛋白衍生物 |
GB9808734D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9811260D0 (en) | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
GB9814902D0 (en) | 1998-07-10 | 1998-09-09 | Univ Nottingham | Screening of neisserial vaccine candidates against pathogenic neisseria |
US6951652B2 (en) | 1998-07-29 | 2005-10-04 | Biosynth S.R.L. | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases |
GB9820003D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
ES2246093T3 (es) | 1998-10-16 | 2006-02-01 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Patogenicida molecular que induce una resistencia a la enfermedad en las plantas. |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
WO2000026384A1 (en) | 1998-11-03 | 2000-05-11 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Lps with reduced toxicity from genetically modified gram negative bacteria |
WO2000055327A2 (en) | 1999-03-12 | 2000-09-21 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
CA2373236C (en) | 1999-05-19 | 2014-08-26 | Chiron S.P.A. | Combination neisserial compositions |
EP1218512A2 (en) | 1999-06-18 | 2002-07-03 | Elitra Pharmaceuticals, Inc. | Nucleotide sequences of moraxella catarrhalis genome |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
US7947291B2 (en) | 2000-01-25 | 2011-05-24 | The University Of Queensland | Modified surface antigen |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
CA2493124C (en) | 2002-08-02 | 2014-04-29 | Glaxosmithkline Biologicals S.A. | Vaccine |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
KR20060019515A (ko) * | 2003-04-16 | 2006-03-03 | 와이어쓰 홀딩스 코포레이션 | 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물 |
US7628995B2 (en) * | 2003-12-23 | 2009-12-08 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicles and uses thereof |
JP4993750B2 (ja) * | 2005-01-27 | 2012-08-08 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のための、gna1870を基にした小胞ワクチン |
JP5275982B2 (ja) * | 2006-06-12 | 2013-08-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
GB0700562D0 (en) * | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
US20100285465A1 (en) * | 2007-08-02 | 2010-11-11 | Glaxosmithkline Biologicals S.A. | Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis |
EP2265640B1 (en) | 2008-03-10 | 2015-11-04 | Children's Hospital & Research Center at Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
MX2010012999A (es) * | 2008-05-30 | 2012-03-07 | U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso. |
GB0816447D0 (en) | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
GB0819633D0 (en) * | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
CN104548082A (zh) * | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
MX2012004850A (es) * | 2009-10-27 | 2012-05-22 | Novartis Ag | Polipeptidos fhbp meningococicos modificados. |
CN103002910A (zh) * | 2010-03-10 | 2013-03-27 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物 |
US9473463B2 (en) | 2014-07-29 | 2016-10-18 | Combined Conditional Access Development & Support, LLC | Control word and associated entitlement control message caching and reuse |
-
2011
- 2011-03-10 CN CN2011800220453A patent/CN103002910A/zh active Pending
- 2011-03-10 US US13/583,064 patent/US20130004530A1/en not_active Abandoned
- 2011-03-10 BR BR112012022676A patent/BR112012022676A2/pt not_active IP Right Cessation
- 2011-03-10 CA CA2792683A patent/CA2792683A1/en not_active Abandoned
- 2011-03-10 BR BR112012022669A patent/BR112012022669A2/pt not_active IP Right Cessation
- 2011-03-10 JP JP2012556522A patent/JP2013521326A/ja active Pending
- 2011-03-10 US US13/583,314 patent/US9567377B2/en active Active
- 2011-03-10 CA CA2792689A patent/CA2792689A1/en not_active Abandoned
- 2011-03-10 WO PCT/EP2011/053630 patent/WO2011110634A1/en active Application Filing
- 2011-03-10 EP EP11707193A patent/EP2544713A1/en not_active Withdrawn
- 2011-03-10 WO PCT/EP2011/053632 patent/WO2011110636A1/en active Application Filing
- 2011-03-10 CA CA2792687A patent/CA2792687A1/en not_active Abandoned
- 2011-03-10 EP EP11707192A patent/EP2544712A1/en not_active Withdrawn
- 2011-03-10 CN CN2011800231068A patent/CN102869377A/zh active Pending
- 2011-03-10 EP EP11708449A patent/EP2544714A1/en not_active Withdrawn
- 2011-03-10 US US13/583,163 patent/US20130011429A1/en not_active Abandoned
- 2011-03-10 CN CN2011800231104A patent/CN102869378A/zh active Pending
- 2011-03-10 WO PCT/EP2011/053631 patent/WO2011110635A1/en active Application Filing
- 2011-03-10 JP JP2012556521A patent/JP2013521770A/ja active Pending
- 2011-03-10 JP JP2012556523A patent/JP2013521327A/ja active Pending
- 2011-03-10 BR BR112012022688A patent/BR112012022688A2/pt not_active IP Right Cessation
-
2016
- 2016-12-06 US US15/370,450 patent/US20170209562A1/en not_active Abandoned
-
2017
- 2017-02-02 JP JP2017017175A patent/JP2017114874A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2013521327A (ja) | 2013-06-10 |
WO2011110635A1 (en) | 2011-09-15 |
CN103002910A (zh) | 2013-03-27 |
CA2792687A1 (en) | 2011-09-15 |
BR112012022676A2 (pt) | 2019-09-24 |
CN102869378A (zh) | 2013-01-09 |
CN102869377A (zh) | 2013-01-09 |
WO2011110636A1 (en) | 2011-09-15 |
US9567377B2 (en) | 2017-02-14 |
EP2544714A1 (en) | 2013-01-16 |
JP2013521326A (ja) | 2013-06-10 |
BR112012022669A2 (pt) | 2017-02-14 |
EP2544712A1 (en) | 2013-01-16 |
CA2792689A1 (en) | 2011-09-15 |
US20130004530A1 (en) | 2013-01-03 |
JP2013521770A (ja) | 2013-06-13 |
CA2792683A1 (en) | 2011-09-15 |
JP2017114874A (ja) | 2017-06-29 |
US20130045231A1 (en) | 2013-02-21 |
EP2544713A1 (en) | 2013-01-16 |
US20170209562A1 (en) | 2017-07-27 |
US20130011429A1 (en) | 2013-01-10 |
WO2011110634A1 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012022688A2 (pt) | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão | |
BR112012022800A2 (pt) | composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica | |
MX2019012081A (es) | Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso. | |
Ellebedy et al. | Re-engaging cross-reactive memory B cells: the influenza puzzle | |
BR112013005427A2 (pt) | composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica. | |
EP3058954A3 (en) | Immunogenic compositions and methods | |
BRPI1008145B8 (pt) | Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica | |
BR112015001390A2 (pt) | vacina de proteína de fusão multimérica e imunoterápicos | |
ECSP10010723A (es) | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso | |
NZ701881A (en) | Vaccines for hsv-2 | |
BR112014004860A2 (pt) | composições de anticorpo contra vírus da influenza | |
DOP2013000235A (es) | Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae. | |
BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
BR112012016982A2 (pt) | "bactérias probióticas recombinantes para a prevenção e tratamento da doença inflamatória do intestino (ibd) e síndrome do intestino irritável (ibs)". | |
BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
BR112015000585A2 (pt) | cepas mutantes de mycoplasma hyopneumoniae | |
BR112018011310A2 (pt) | mutante da proteína l1 do papilomavírus humano tipo 58 | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
BR112014031386A2 (pt) | vacinas para meningococos do sorogrupo x | |
BR112014001516A2 (pt) | peptídeos e proteínas do vírus polioma jc nas aplicações de vacinação e de diagnóstico | |
BR112015023738B8 (pt) | Vacinas de nucleoproteina influenza | |
BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo | |
BR112013010338A2 (pt) | composição, métodos para preparar uma composição imunogênica, para adjuvantar uma resposta imune, para eliciar uma resposta imune contra um agente infeccioso, para evitar e/ou reduzir a deposição de amilóide ou doença de alzheimer em um indivíduo, e para tratar/reduzir/melhorar a infecção por uma agente infeccioso, uso de uma proteína, e, kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |